Acknowledging the kind of traction gained by this market, recently published a study report asserts the global Budesonide Market size is projected to accrue voluminously by 2029 registering a phenomenal CAGR of 9.23% during the review period (2022 to 2029).
Budesonide Market Overview
Budesonide is an asthma medicine that helps to avoid symptoms. It's a steroid or corticosteroid (cortisone-like medicine). The medicine reduces the intensity of asthma attacks by preventing inflammation in the lungs. Other asthma medications, such as bronchodilators, may be combined with inhaled budesonide to open up restricted breathing airways in the lungs. AstraZeneca developed budesonide, an adrenocortical hormone, in the 1990s. It is mostly used to treat non-budesonide glucocorticoid-dependent.
Asthma and other respiratory problems have become more prevalent in recent years as a result of rising air pollution levels. With the constant rise in asthma cases, demand for budesonide is expected to rise. Budesonide is a medication that helps people with mild to moderate Crohn's disease. Entocortec, uceris, pulmicort, pulmicort flexhaler, pulmicort respules, and rhinocort are all brand names for budesonide, which is a prescription medicine. It’s also a component of the symbicort inhaler, which is used to treat COPD and asthma. In the near future
What is our Budesonide Market report scope?
Report Attributes
|
Report Details
|
Forecast Period 2022 to 2029 CAGR
|
CAGR of 9.23 % during the review period (2022 to 2029).
|
By Type
|
- Injectable Suspension
- Aerosols
- Inhalation Powder
- Tablet and Capsule
|
By Application
|
- Respiratory Disease Treatment
- Nose Disease Treatment
- Inflammatory Bowel Disease Treatment
- Others
|
By Companies
|
AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod
|
Regions Covered
|
- North America
- Europe
- Asia-Pacific
- Rest of the World
|
Countries Covered
|
- US
- Canada
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
|
Base Year
|
2022
|
Historical Year
|
2017 to 2021
|
Forecast Year
|
2022 to 2029
|
Number of Pages
|
160
|
Customization Available
|
Yes, the report can be customized as per your needs
|
Frequently Asked Questions
What is the study period of this market?
The Budesonide Market is studied from 2017 - 2029.
What is the growth rate of Budesonide Market?
The Budesonide Market is growing at a CAGR of 9.23 % over the next forecast years.
Who are the key players in Budesonide Market?
AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod
What region does this Budesonide Market report covers?
North America (the United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, and Italy)
Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Budesonide Market?
Injectable Suspension, Aerosols, Inhalation Powder, Tablet and Capsule
What are the major end-use applications of Budesonide Market?
Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Others
Who are the Major Players in Budesonide Market?
The Budesonide Market is growing at a very fast pace and has seen the focus of many local and regional vendors offering precise application products for multiple end users. The three dependencies for the status of major companies in the market are: company profile, profitable gross margin, the prices they charge. These are the main players in this market AstraZeneca (LON: AZN), Teva (TLV: TEVA), Mylan (NASDAQ: VTRS), Sandoz, Cosmo Pharmaceuticals (SWX: COPN), Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod and others.
Industry News:
23 December 2019 :AstraZeneca announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
March 16, 2022 Viatris Inc. (NASDAQ: VTRS) and Kindeva Drug Delivery L.P. today announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca's Symbicort®. Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be available in 160 mcg/4.5 mcg and 80 mcg/4.5 mcg dosage strengths.
JULY 09, 2018 Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Uceris®1 (budesonide) extended-release tablets, 9 mg, in the U.S.
What are the major Applications, Types and Regions for Budesonide Market?
By Type, it is segmented into
- Injectable Suspension
- Aerosols
- Inhalation Powder
- Tablet and Capsule
By Applications it is segmented into
- Respiratory Disease Treatment
- Nose Disease Treatment
- Inflammatory Bowel Disease Treatment
- Others
Budesonide Market Regional Analysis
Asia Pacific has a substantial market share in the budesonide industry when compared to other regions. In the foreseeable future, due to rising population and environmental issues in this region, particularly in India and China.China is projected to dominate the budesonide business. Budesonide's market share in Asia Pacific is predicted to increase in the next years. Following Europe, North America is likely to experience tremendous growth in the next years. During the forecast period, Latin America and the Middle East and Africa are expected to grow at a slow pace.
The market for Budesonide in Asia is predicted to increase rapidly over the next few years, followed by Europe. In Asia, China and India are likely to be the fastest expanding markets.
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of the World
- Middle East & Africa
- Latin America
The Budesonide Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Budesonide Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Key Insights
- Pricing Analysis, By Key Regions, 2022
- Price Comparison (USD Per Ton) By Type (Injectable Suspension, Aerosols, Inhalation Powder, Tablet and Capsule) 2021/2022
- Price Comparison (USD, Per Ton): By Application (Respiratory Disease Treatment, Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Others) 2021/2022
- Impact of COVID-19 on the Budesonide Market
- Production Share of Budesonide, By Region, 2022
- Key Industry Developments
- Global Budesonide Market Analysis, Insights and Forecast, 2022-2029
- Market Analysis, Insights and Forecast – By Application
- Respiratory Disease Treatment
- Nose Disease Treatment
- Inflammatory Bowel Disease Treatment
- Others
- Market Analysis, Insights and Forecast – By Type
- Injectable Suspension
- Aerosols
- Inhalation Powder
- Tablet and Capsule
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Rest of World
- Competitive Analysis
- Global Market Share Analysis (2021)
- Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- AstraZeneca
- Overview,
- Products,
- SWOT analysis,
- Recent developments,
- strategies,
- financials (based on availability)
- Teva
- Overview,
- Products,
- SWOT analysis,
- Recent developments,
- strategies,
- financials (based on availability)
- Mylan
- Overview,
- Products,
- SWOT analysis,
- Recent developments,
- strategies,
- financials (based on availability)
- Sandoz
- Overview,
- Products,
- SWOT analysis,
- Recent developments,
- strategies,
- financials (based on availability)
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.